NASDAQ | TSX: ACB
EDMONTON, AB, April 26,
2023 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:
ACB), the Canadian company opening the world to cannabis, today
announced the launch of a new tracking program designed to support
and empower cannabis patients on their wellness journey.
Alongside the advice of a healthcare professional, Aurora
patients can use the award-winning Strainprint® App
journal to track their medical cannabis journey by logging their
symptoms and consumption habits to better understand which strains,
THC and CBD levels, ingestion methods and doses best work for them.
Patients can also explore new products, learn more about strains
and understand what has helped other patients through the App. All
data entered and gathered by the Strainprint App is anonymous and
aggregated.
"We take a patient-first approach to cannabis and are proud to
provide our patients with programs that improve their lives and
their medical cannabis journey," says Mike
Jones, SVP of Medical at Aurora Cannabis. "By working with
Strainprint, we can support our patients every step of the way, and
further Aurora's promise to prioritize patient well-being and
provide the highest quality products."
Patients can download the free Strainprint App on the Apple
Store and Google Play Store.
About Strainprint
Based in Toronto, Canada,
Strainprint® Technologies is the leading data and
analytics technology platform for medical and recreational cannabis
use research. Since 2016, Strainprint® has
been providing decision-support research tools and data
to cannabis patients, doctors, licensed producers, retailers,
industry regulators, academic researchers and
pharmaceutical/biotechnology companies across Canada, the U.S., Australia, Israel and New Zealand. With over 2.1
million real-time user-interactions logged against 9,500+ legal and
lab-tested cannabis products on the Strainprint®
platform (over 100 million data points),
Strainprint® is also the most extensive real-world
evidence (RWE) study on therapeutic cannabis use and its impact on
over 300 therapeutic conditions and symptoms - Cannabis Big
Data®! Strainprint data is regularly published in
peer-reviewed research journals, providing credibility, plus
data-backed insight and formulation guidance for cannabis
processors, pharmaceutical and therapeutics manufacturers and
consumer packaged goods companies in the cosmetics, food and
beverage industries. Strainprint Analytics can be seamlessly
integrated with most electronic medical records, seed2sale,
and point-of-sale software systems. The Strainprint
journal App is free to patients and can be downloaded from both
the IOS App Store
and Google Play
Store. www.strainprint.ca, facebook, twitter, linkedin.
For Inquiries: info@strainprint.ca
About Aurora
Aurora is opening the world to cannabis, serving both the
medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Whistler, Being and Greybeard, as well
as CBD brands, Reliva and KG7. Medical cannabis brands include
MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. as
well as international brands, Pedanios, Bidiol and CraftPlant.
Aurora also has a controlling interest in Bevo Farms Ltd.,
North America's leading supplier
of propagated agricultural plants. Driven by science and
innovation, and with a focus on high-quality cannabis products,
Aurora's brands continue to break through as industry leaders in
the medical, performance, wellness and adult recreational markets
wherever they are launched. Learn more at www.auroramj.com and
follow us on Twitter and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
Forward Looking
Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include, but are not limited to, statements regarding the
launch of the Strainprint app and the associated benefits for
patients of the Company.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations, management's estimation that SG&A will grow only in
proportion of revenue growth, the ability to expand and maintain
distribution capabilities, the impact of competition, the general
impact of financial market conditions, the yield from cannabis
growing operations, product demand, changes in prices of required
commodities, competition, and the possibility for changes in laws,
rules, and regulations in the industry, epidemics, pandemics or
other public health crises, including the current outbreak of
COVID-19, and other risks, uncertainties and factors set out under
the heading "Risk Factors" in the Company's annual information form
dated September 20, 2022 (the "AIF")
and filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com and filed
with and available on the SEC's website at www.sec.gov. The Company
cautions that the list of risks, uncertainties and other factors
described in the AIF is not exhaustive and other factors could also
adversely affect its results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-partners-with-strainprint-to-empower-patients-on-their-cannabis-journey-301808361.html
SOURCE Aurora Cannabis Inc.